Exelixis EXEL Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:ReceivablesNetCurrent.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's accounts receivable?
- Exelixis (EXEL) reported accounts receivable of $328.95M in Q1 2026.
- How has Exelixis's accounts receivable changed year-over-year?
- Exelixis's accounts receivable increased by 16.8% year-over-year, from $281.64M to $328.95M.
- What is the long-term trend for Exelixis's accounts receivable?
- Over 5 years (2020 to 2025), Exelixis's accounts receivable has grown at a 12.3% compound annual growth rate (CAGR), from $160.88M to $286.92M.
- What does accounts receivable mean?
- The amount of money customers owe the company for products already delivered.
- How do you interpret accounts receivable?
- An increase relative to revenue may signal collection issues or changes in customer payment terms, while a decrease indicates efficient cash conversion.
- How does accounts receivable compare across companies?
- Common in commercial-stage pharmaceutical companies; peers with similar distribution models should have comparable days sales outstanding.